Markets HCW starts Entasis Therapeutics at buy; PT $18 H.C. Wainwright initiated coverage of Entasis Therapeutics (NASDAQ:ETTX) with a “buy” rating and $18 price target. The stock closed at $8.25 on Aug. 16. Spun out of AstraZeneca in 2015, Entasis is focused on novel... August 19, 2019